

# Mohamed A Kharfan-Dabaja

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1146320/publications.pdf>

Version: 2024-02-01

258  
papers

5,901  
citations

87888

38  
h-index

110387

64  
g-index

268  
all docs

268  
docs citations

268  
times ranked

6526  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. <i>Blood</i> , 2016, 127, 938-947.	1.4	246
2	A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 290-299.	9.1	224
3	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 3141-3149.	1.6	212
4	CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071984158.	2.5	160
5	Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1826-1838.	2.0	135
6	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2305-2321.	2.0	132
7	Efficacy of Rituximab in the Setting of Steroid-Refractory Chronic Graft-versus-Host Disease: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1005-1013.	2.0	116
8	&lt;p&gt;&lt;/p&gt;Cytokine Release Syndrome: Current Perspectives&lt;/p&gt;. <i>ImmunoTargets and Therapy</i> , 2019, Volume 8, 43-52.	5.8	116
9	Allogeneic transplantation provides durable remission in a subset of <sc>DLBCL</sc> patients relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2016, 174, 235-248.	2.5	115
10	A Randomized Phase II Trial Comparing Tacrolimus and Mycophenolate Mofetil to Tacrolimus and Methotrexate for Acute Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 937-947.	2.0	101
11	Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse. <i>JAMA Oncology</i> , 2018, 4, 1245.	7.1	97
12	The risk and prognosis of COVID-19 infection in cancer patients: A systematic review and meta-analysis. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2020, , .	0.9	97
13	Extracorporeal Photopheresis in Steroid-Refractory Acute or Chronic Graft-versus-Host Disease: Results of a Systematic Review of Prospective Studies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1677-1686.	2.0	95
14	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with <i>FLT3</i>-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2020, 105, 1507-1516.	3.5	91
15	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	5.2	89
16	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2117-2125.	2.0	87
17	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)â€“an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). <i>Bone Marrow Transplantation</i> , 2019, 54, 1868-1880.	2.4	86
18	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e76-e85.	2.0	85

#	ARTICLE	IF	CITATIONS
19	A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2012, 97, 1882-1889.	3.5	82
20	Improved survival after acute graft-versus-host disease diagnosis in the modern era. <i>Haematologica</i> , 2017, 102, 958-966.	3.5	79
21	Diagnostic and Therapeutic Advances in Blastic Plasmacytoid Dendritic Cell Neoplasm: A Focus on Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1006-1012.	2.0	75
22	Râ€œCHOP </scp> <i>versus</i> doseâ€œadjusted Râ€œEPOCH</scp> in frontline management of primary mediastinal Bâ€œcell lymphoma: a multiâ€œcentre analysis. <i>British Journal of Haematology</i> , 2018, 180, 534-544.	2.5	70
23	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 642-649.	1.2	65
24	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	5.2	63
25	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016, 34, 1864-1871.	1.6	61
26	Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2012, 87, 1006-1009.	4.1	60
27	Allogeneic haematopoietic cell transplantation for extranodal natural killer/Tâ€œcell lymphoma, nasal type: a <scp>CIBMTR</scp> analysis. <i>British Journal of Haematology</i> , 2018, 182, 916-920.	2.5	59
28	Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. <i>British Journal of Haematology</i> , 2017, 179, 781-789.	2.5	56
29	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2091-2099.	2.0	55
30	Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. <i>Blood</i> , 2022, 139, 1330-1339.	1.4	52
31	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2181-2189.	2.0	51
32	Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia. <i>Journal of Hematology and Oncology</i> , 2010, 3, 36.	17.0	47
33	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. <i>Leukemia</i> , 2019, 33, 2767-2778.	7.2	47
34	Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1254-1265.	2.4	47
35	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. <i>Cancer</i> , 2020, 126, 5077-5087.	4.1	47
36	Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 6-20.	1.2	45

#	ARTICLE	IF	CITATIONS
37	Rituximab for prevention and treatment of graft-versus-host disease. <i>International Journal of Hematology</i> , 2011, 93, 578-585.	1.6	44
38	Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation. <i>JAMA Oncology</i> , 2019, 5, 715.	7.1	44
39	Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. <i>JAMA Oncology</i> , 2021, 7, 993.	7.1	44
40	Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. <i>Immunotherapy</i> , 2013, 5, 457-466.	2.0	41
41	Influenza A/pandemic 2009/H1N1 in the setting of allogeneic hematopoietic cell transplantation: a potentially catastrophic problem in a vulnerable population. <i>International Journal of Hematology</i> , 2010, 91, 124-127.	1.6	39
42	Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. <i>JAMA Oncology</i> , 2020, 6, 1011.	7.1	39
43	Clinical Outcomes of Patients With Plasma Cell Leukemia in the Era of Novel Therapies and Hematopoietic Stem Cell Transplantation Strategies: A Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 507-511.	0.4	37
44	Allotransplantation for Patients Age $\geq 40$ Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.	2.0	37
45	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphomas as Front-Line Consolidation or in the Relapsed/Refractory Setting: A Systematic Review/Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 802-814.	2.0	37
46	Allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia (ALL) in first complete remission. <i>The Cochrane Library</i> , 2011, , CD008818.	2.8	36
47	Antithymocyte globulin for graft-versus-host disease prophylaxis: an updated systematic review and meta-analysis. <i>Bone Marrow Transplantation</i> , 2019, 54, 1094-1106.	2.4	36
48	Fludarabine and Pharmacokinetic-Targeted Busulfan before Allografting for Adults with Acute Lymphoid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1505-1511.	2.0	35
49	Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis. <i>British Journal of Haematology</i> , 2013, 163, 315-325.	2.5	35
50	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35
51	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
52	Nonmyeloablative Alternative Donor Transplantation for Hodgkin and Non-Hodgkin Lymphoma: From the LWP-EBMT, Eurocord, and CIBMTR. <i>Journal of Clinical Oncology</i> , 2020, 38, 1518-1526.	1.6	34
53	Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2008, 113, 897-906.	4.1	33
54	Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Myeloid Leukemia. <i>Cancer Control</i> , 2011, 18, 237-245.	1.8	33

#	ARTICLE	IF	CITATIONS
55	Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation. The Cochrane Library, 2014, 2014, CD010280.	2.8	33
56	IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. Haematologica, 2017, 102, 948-957.	3.5	33
57	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncology, 2022, 8, 404.	7.1	32
58	Current Status of Allogeneic Hematopoietic Stem Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria. Biology of Blood and Marrow Transplantation, 2009, 15, 656-661.	2.0	30
59	Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant. Blood Advances, 2020, 4, 3435-3442.	5.2	30
60	Allogeneic Hematopoietic Cell Transplantation Is an Effective Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm in First Complete Remission: Systematic Review and Meta-analysis. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 703-709.e1.	0.4	29
61	Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. Journal of Hematology and Oncology, 2019, 12, 6.	17.0	29
62	Hematopoietic Stem Cell Allografting for Chronic Lymphocytic Leukemia: A Focus on Reduced-Intensity Conditioning Regimens. Cancer Control, 2012, 19, 68-75.	1.8	28
63	Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. Immunotherapy, 2016, 8, 435-447.	2.0	28
64	Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation. Blood Cancer Journal, 2021, 11, 49.	6.2	28
65	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. Blood Advances, 2018, 2, 933-940.	5.2	27
66	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia, 2020, 34, 3338-3347.	7.2	27
67	Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma?. Radiotherapy and Oncology, 2022, 166, 171-179.	0.6	27
68	Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. Annals of Transplantation, 2010, 15, 21-9.	0.9	27
69	Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, 76-82.	2.0	26
70	A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Advances, 2021, 5, 1154-1163.	5.2	26
71	<i>In vivo</i> IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. Haematologica, 2018, 103, 531-539.	3.5	25
72	Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials. Current Research in Translational Medicine, 2020, 68, 159-170.	1.8	24

#	ARTICLE	IF	CITATIONS
73	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma—type Richter syndrome. <i>Blood Advances</i> , 2021, 5, 3528-3539.	5.2	24
74	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia: An Evolving Concept. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 373-385.	2.0	23
75	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	3.5	23
76	Granulocytic Sarcoma Presenting with Malignant Anasarca in a Patient with Secondary Acute Myeloid Leukemia. <i>International Journal of Hematology</i> , 2004, 79, 250-252.	1.6	22
77	Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2330-2337.	2.0	22
78	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 270-278.	2.0	21
79	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 472-479.	2.0	21
80	Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 58-66.	1.2	21
81	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2911-2921.	2.4	21
82	Severe Hypoalbuminemia at Day 90 Predicts Worse Nonrelapse Mortality and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 384-393.	2.0	20
83	Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 117.	17.0	20
84	Pretransplantation 5-Azacitidine in High-Risk Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 776-780.	2.0	19
85	Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease. <i>Haematologica</i> , 2015, 100, 970-977.	3.5	19
86	Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2020, 190, 573-582.	2.5	19
87	Emerging Role of CD20 Blockade in Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1347-1354.	2.0	18
88	TP53 and IDH2 Somatic Mutations Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 753-758.	0.4	18
89	Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e35-e39.	0.4	18
90	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	5.2	18

#	ARTICLE	IF	CITATIONS
91	Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 48.e1-48.e10.	1.2	18
92	Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review. <i>Future Oncology</i> , 2016, 12, 2631-2642.	2.4	17
93	CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. <i>Bone Marrow Transplantation</i> , 2020, 55, 1525-1532.	2.4	17
94	Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 33-40.	0.9	17
95	Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 592-601.	2.5	17
96	Enteropathy-Associated T cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 140-147.	2.3	17
97	Outcomes of rituximab+BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. <i>Cancer</i> , 2020, 126, 2279-2287.	4.1	17
98	Clotrimazole troches induce supratherapeutic blood levels of sirolimus and tacrolimus in an allogeneic hematopoietic cell-transplant recipient resulting in acute kidney injury. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2016, 9, 157-161.	0.9	16
99	Reduced intensity is preferred over myeloablative conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: A systematic review/meta-analysis. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 53-64.	0.9	16
100	Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis. <i>Cancer</i> , 2019, 125, 4417-4425.	4.1	16
101	Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. <i>Blood Advances</i> , 2022, 6, 920-930.	5.2	16
102	Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications. <i>International Journal of Hematology</i> , 2011, 93, 206-212.	1.6	15
103	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9.	1.2	15
104	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. <i>Cancer</i> , 2021, 127, 82-92.	4.1	15
105	Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 923.e1-923.e12.	1.2	15
106	Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia after Ibrutinib Discontinuation Outside Clinical Trials: A Single Institution Experience. <i>Blood</i> , 2015, 126, 2945-2945.	1.4	15
107	Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia: A Comprehensive Review. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 997-1004.	2.0	14
108	Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2014, 38, 1165-1172.	0.8	14

#	ARTICLE	IF	CITATIONS
109	Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft-versus-Host Disease: Phase I Trial Results. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1074-1082.	2.0	14
110	Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation. <i>Expert Review of Vaccines</i> , 2015, 14, 341-350.	4.4	14
111	Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience. <i>Leukemia Research</i> , 2018, 67, 1-5.	0.8	14
112	Efficacy of Allogeneic Hematopoietic Cell Transplantation in Human T Cell Lymphotropic Virus Type 1 Associated Adult T Cell Leukemia/Lymphoma: Results of a Systematic Review/Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1695-1700.	2.0	14
113	What is the role of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia?. <i>Bone Marrow Transplantation</i> , 2020, 55, 325-331.	2.4	14
114	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.	2.0	14
115	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1784-1802.	2.0	14
116	A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. <i>EClinicalMedicine</i> , 2021, 33, 100787.	7.1	14
117	Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e694-e711.	0.4	13
118	The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1137-1143.	2.0	13
119	An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077.	2.4	13
120	Phase II Study of CD4+-Guided Pentostatin Lymphodepletion and Pharmacokinetically Targeted Busulfan as Conditioning for Hematopoietic Cell Allografting. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1087-1093.	2.0	12
121	A Critical Appraisal of Extracorporeal Photopheresis as a Treatment Modality for Acute and Chronic Graft-Versus-Host Disease. <i>Biomedicines</i> , 2017, 5, 60.	3.2	12
122	Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading models. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 1-6.	0.9	12
123	Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 621-629.	2.2	12
124	Monoclonal Antibodies in Conditioning Regimens for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1288-1300.	2.0	11
125	A new dawn for gemtuzumab ozogamicin?. <i>Lancet Oncology</i> , The, 2014, 15, 913-914.	10.7	11
126	Hematopoietic Cell Transplantation for Richter Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1938-1944.	2.0	11

#	ARTICLE	IF	CITATIONS
127	Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis. <i>Blood Cancer Journal</i> , 2019, 9, 97.	6.2	11
128	Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 165.e1-165.e11.	1.2	11
129	Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions. <i>International Journal of Hematologic Oncology</i> , 2021, 10, IJH33.	1.6	11
130	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 921.e1-921.e10.	1.2	11
131	Allogeneic Hematopoietic Cell Transplantation for Adult Philadelphia-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 949-958.	2.0	10
132	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	7.0	10
133	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2194-2202.	2.4	10
134	Reanalysis of TransVax immunogenicity. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 18.	9.1	9
135	Hypoalbuminaemia segregates different prognostic subgroups within the refined standard risk acute graft-versus-host disease score. <i>British Journal of Haematology</i> , 2018, 180, 854-862.	2.5	9
136	Outcomes of Hepatosplenic T-Cell Lymphoma: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 106-112.e1.	0.4	9
137	Systematic review of high dose chemotherapy and autologous haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: what is the published evidence?. <i>British Journal of Haematology</i> , 2007, 139, 234-242.	2.5	8
138	Myeloablative Intravenous Pharmacokinetically Targeted Busulfan Plus Fludarabine As Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 335-340.	0.4	8
139	Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation. <i>Immunotherapy</i> , 2015, 7, 1059-1071.	2.0	8
140	Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2018, 53, 1434-1444.	2.4	8
141	Using prognostic models in CLL to personalize approach to clinical care: Are we there yet?. <i>Blood Reviews</i> , 2018, 32, 159-166.	5.7	8
142	Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study. <i>Leukemia and Lymphoma</i> , 2019, 60, 309-316.	1.3	8
143	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2020, 191, 442-452.	2.5	8
144	Systematic Review/Meta-Analysis on Efficacy of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease: An International Effort on Behalf of the Pediatric Diseases Working Party of European Society for Blood and Marrow Transplantation and the Sickle Cell Transplantation International Consortium. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 167.e1-167.e12.	1.2	8

#	ARTICLE	IF	CITATIONS
145	A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients with Refractory Large B-Cell Lymphoma (ZUMA-14). <i>Blood</i> , 2019, 134, 4093-4093.	1.4	8
146	Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies. <i>Clinical Hematology International</i> , 2019, 1, 2.	1.7	8
147	Umbilical cord blood transplantation induces a durable remission in hepatosplenic gammaδ T cell lymphoma with associated hemophagocytic lymphohistiocytosis. <i>American Journal of Hematology</i> , 2014, 89, 934-935.	4.1	7
148	Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 54-66.	1.7	7
149	Primary plasmacytoma involving mediastinal lymph nodes: A diagnostic mimicry of primary mediastinal lymphoma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2016, 9, 26-29.	0.9	7
150	Thymoma with Concomitant Pure Red Cell Aplasia, Good's Syndrome and Myasthenia Gravis Responding to Rituximab. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2016, 32, 219-222.	0.6	7
151	Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 1-12.	0.9	7
152	Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 59-68.	1.3	7
153	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 2811-2820.	1.3	7
154	Diagnosis and treatment of subcutaneous panniculitis-like T-cell lymphoma: A systematic literature review. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.9	7
155	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 720-728.	1.2	7
156	Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1099-1105.	2.0	7
157	ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 523-529.	1.2	7
158	Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 267.e1-267.e5.	1.2	6
159	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	2.4	6
160	Cellular Therapies for Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 363-370.	1.2	6
161	Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease "a real-world outcomes analysis. <i>British Journal of Haematology</i> , 2021, 195, 429-432.	2.5	6
162	A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention. <i>Blood Advances</i> , 2021, 5, 2740-2750.	5.2	6

#	ARTICLE	IF	CITATIONS
163	Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 911.e1-911.e7.	1.2	6
164	Comparative study of therapy-related and de novo adult B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2022, 196, 963-968.	2.5	6
165	Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant. <i>British Journal of Haematology</i> , 2022, 197, 212-222.	2.5	6
166	Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS). <i>Blood Cancer Journal</i> , 2022, 12, 62.	6.2	6
167	Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	6
168	Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 610-617.	1.2	6
169	Guadecitabine for AML and MDS: hype or hope?. <i>Lancet Oncology</i> , The, 2015, 16, 1009-1011.	10.7	5
170	Integrating Genomics in Myelodysplastic Syndrome to Predict Outcomes After Allogeneic Hematopoietic Cell Transplantation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 7-13.	0.4	5
171	Haploidentical transplantation as a promising therapy for relapsed hemophagocytic lymphohistiocytosis in an older adult patient. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 96-98.	0.9	5
172	Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 400-405.	2.0	5
173	Association Between High-grade Myelodysplastic Syndrome and Cutaneous Langerhans Cell Histiocytosis Suggested by Next-Generation Sequencing. <i>JAMA Dermatology</i> , 2020, 156, 817.	4.1	5
174	C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 141-146.	0.9	5
175	Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2021, 195, 757-763.	2.5	5
176	Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: What is the evidence?. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.9	5
177	A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. <i>Blood Advances</i> , 2022, 6, 259-269.	5.2	5
178	Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after three or more lines of prior therapy: evidence of durable benefit. <i>Haematologica</i> , 2022, 107, 1214-1217.	3.5	5
179	Hematopoietic cell transplantation: Training challenges and potential opportunities through networking and integration of modern technologies to the practice setting. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 184-188.	0.9	4
180	Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e273-e280.	0.4	4

#	ARTICLE	IF	CITATIONS
181	Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. <i>Bone Marrow Transplantation</i> , 2020, 55, 698-707.	2.4	4
182	Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 156.	6.2	4
183	Driving Out Chronic Lymphocytic Leukemia With CAR T Cells. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 5-17.	1.2	4
184	Prospect of CAR T-cell therapy in acute myeloid leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 211-220.	4.1	4
185	Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience. <i>Leukemia and Lymphoma</i> , 2022, 63, 1363-1368.	1.3	4
186	Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 668.e1-668.e6.	1.2	4
187	Bortezomib plus dexamethasone results in a late organ response in primary heavy-chain amyloidosis without a hematologic response. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2015, 8, 138-139.	0.9	3
188	Predictors of outcome in reduced intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: summarizing the evidence and highlighting the limitations. <i>Immunotherapy</i> , 2015, 7, 47-56.	2.0	3
189	Acute pericarditis and tamponade from Coxsackie B3 in an adult Hematopoietic-Cell-Allograft recipient: A rare but potentially serious complication. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2016, 9, 82-85.	0.9	3
190	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 486-493.	2.0	3
191	Intraocular involvement of Mantle cell lymphoma: A case report and literature review. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, 14, 147-152.	0.9	3
192	Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. <i>European Journal of Haematology</i> , 2021, 107, 48-53.	2.2	3
193	Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7522-7522.	1.6	3
194	Tandem Versus Single Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials (RCT).. <i>Blood</i> , 2007, 110, 936-936.	1.4	3
195	Phase II Study of Lenalidomide in Combination with Rituximab for Patients with CD5+/CD20+ Hematologic Malignancies Who Relapse or Progress After Rituximab. Interim Analysis.. <i>Blood</i> , 2009, 114, 2376-2376.	1.4	3
196	Proton Therapy as a Bridging Treatment in CAR T-Cell Therapy for Relapsed and Refractory Large B-Cell Lymphoma: Is There a Role?. <i>International Journal of Particle Therapy</i> , 2020, 7, 13-20.	1.8	3
197	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. <i>Blood</i> , 2021, 138, 2527-2527.	1.4	3
198	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10.	1.2	3

#	ARTICLE	IF	CITATIONS
199	Feasibility and Efficacy of High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation for HIV-Associated Lymphoma: A Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 548-551.	0.4	2
200	Efficacy of proteasome inhibitor-based maintenance following autologous transplantation in multiple myeloma: A systematic review and meta-analysis. <i>European Journal of Haematology</i> , 2021, 106, 40-48.	2.2	2
201	Efficacy of allogeneic hematopoietic cell transplantation in patients with chronic phase CML resistant or intolerant to tyrosine kinase inhibitors. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.9	2
202	Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e89-e95.	0.4	2
203	Predictors and management of relapse to axicabtagene ciloleucel in patients with aggressive B-cell lymphoma. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2021, , .	0.9	2
204	Omission of day +11 methotrexate dose and allogeneic hematopoietic cell transplantation outcomes: results of a systematic review/meta-analysis. <i>Bone Marrow Transplantation</i> , 2022, 57, 65-71.	2.4	2
205	Response to COVID-19 Vaccination Post-CAR T Therapy in Patients with Non-Hodgkin Lymphoma and Multiple Myeloma. <i>Blood</i> , 2021, 138, 1750-1750.	1.4	2
206	Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. <i>Hematological Oncology</i> , 2022, 40, 49-57.	1.7	2
207	<i>DDX41</i> Variant of Unknown Significance (VUS) Have Distinct Clinical and Diagnostic Features but Are Associated with Similar Prognosis and Co-Mutation Patterns As Pathogenic <i>DDX41</i> : Analysis of the Mayo Clinic (MC) Myeloid Next-Generation Sequencing (NGS) Cohort. <i>Blood</i> , 2021, 138, 3693-3693.	1.4	2
208	Worldwide Network for Blood and Marrow Transplantation Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 455-462.	1.2	2
209	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e815-e825.	0.4	2
210	Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR/CMWP of EBMT analysis. <i>British Journal of Haematology</i> , 2022, 198, 785-789.	2.5	2
211	In-field recurrences in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) bridged with radiation prior to CD19 chimeric antigen receptor T-cell therapy (CART).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7556-7556.	1.6	2
212	Granulocytic sarcoma and chronic lymphocytic leukemia of the gastrointestinal tract after allogeneic hematopoietic cell transplantation mimicking graft-versus-host disease. <i>Leukemia and Lymphoma</i> , 2008, 49, 350-352.	1.3	1
213	Hope for BET inhibition in patients with leukaemia or lymphoma. <i>Lancet Haematology</i> , the, 2016, 3, e157-e158.	4.6	1
214	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. , 2019, , 185-190.		1
215	Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells. <i>American Journal of Hematology</i> , 2019, 94, E245-E247.	4.1	1
216	Impact of Depression and Anxiety on Opioid Use in Hospitalized Hematopoietic Cell Transplantation Recipients. <i>Psychosomatics</i> , 2020, 61, 363-370.	2.5	1

#	ARTICLE	IF	CITATIONS
217	Fatal Mycobacterium abscessus in a recipient of axicabtagene ciloleucel CAR-T: beware of T cells. Bone Marrow Transplantation, 2020, 55, 1464-1465.	2.4	1
218	Salvage therapies in transplant-eligible relapsed classic Hodgkin lymphoma, are novel regimens better?. Journal of Clinical Oncology, 2021, 39, 7530-7530.	1.6	1
219	Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd. Blood, 2011, 118, 323-323.	1.4	1
220	Conservative Management Vs. Allogeneic Hematopoietic Cell Transplantation For Polycythemia Vera: A Systematic Review and Decision-Analysis. Blood, 2013, 122, 5372-5372.	1.4	1
221	TP53 and IDH2 Somatic Mutations Are Associated with Poor Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Blood, 2015, 126, 4382-4382.	1.4	1
222	Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS. Blood, 2016, 128, 3486-3486.	1.4	1
223	Opiate and Benzodiazepine Use during Hospitalization for Hematopoietic Stem Cell Transplantation (HSCT) Is Associated with Adverse Health Related Outcomes. Blood, 2018, 132, 5873-5873.	1.4	1
224	Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs. Blood Cancer Journal, 2022, 12, .	6.2	1
225	Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia. Lancet Oncology, The, 2016, 17, e1.	10.7	0
226	Recognizing Risk Factors Associated With Unplanned 30-Day Readmissions in Hematopoietic Cell Transplantation. JAMA Network Open, 2019, 2, e196463.	5.9	0
227	Relapse of Hodgkin lymphoma after autologous hematopoietic cell transplantation: A current management perspective. Hematology/ Oncology and Stem Cell Therapy, 2021, 14, 95-103.	0.9	0
228	Impact of time to relapse and response to salvage therapy on post autologous stem cell transplant outcomes in relapsed or refractory diffuse large B-cell lymphoma.. Journal of Clinical Oncology, 2021, 39, e19501-e19501.	1.6	0
229	Patient perceptions of palliative care in the process of allogeneic hematopoietic cell transplantation.. Journal of Clinical Oncology, 2021, 39, e24082-e24082.	1.6	0
230	Effect of time to relapse on overall survival (OS) in mantle cell lymphoma (MCL) patients (pts) following frontline high-dose therapy and autologous hematopoietic cell transplantation (autoHCT).. Journal of Clinical Oncology, 2021, 39, 7521-7521.	1.6	0
231	Diffuse large B-cell lymphoma with leukemic involvement.. Journal of Clinical Oncology, 2021, 39, e19552-e19552.	1.6	0
232	Apheresis of Hematopoietic Progenitor Cell (HPC) From Allogeneic Donors &gt;60 Years of Age.. Blood, 2009, 114, 4226-4226.	1.4	0
233	Salvage Chemotherapy Regimens for Acute Myeloid Leukemia: Is One Better?.. Blood, 2009, 114, 1022-1022.	1.4	0
234	Sirolimus Yields High Response Rates in Hematopoietic Allograft Recipients with Steroid-Refractory Acute Graft-Versus-Host Disease.. Blood, 2009, 114, 2235-2235.	1.4	0

#	ARTICLE	IF	CITATIONS
235	Targeted Intravenous Busulfan and Fludarabine Allogeneic Transplantation Conditioning in Acute Myeloid Leukemia.. Blood, 2009, 114, 2290-2290.	1.4	0
236	Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PBA±R) Using a Novel Principle of CD4-Guided Immune Suppression. Blood, 2011, 118, 3022-3022.	1.4	0
237	Efficacy Of Novel Agents As Maintenance Therapy For Multiple Myeloma: A Direct and Network Meta-Analysis. Blood, 2013, 122, 1945-1945.	1.4	0
238	Impact of Splenomegaly in the Presence of Negative PET FDG Avidity on Allogeneic Hematopoietic Cell Transplant Outcomes in Patients with Lymphoid Malignancies. Blood, 2015, 126, 5524-5524.	1.4	0
239	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T-Cell Lymphomas As Front-Line Consolidation or in the Relapsed/Refractory Setting: A Meta-Analysis. Blood, 2015, 126, 4493-4493.	1.4	0
240	Hypo-Albuminemia at Day+90 after Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies Independently Predicts for Inferior Overall Survival and Higher Non-Relapse Mortality. Blood, 2015, 126, 4407-4407.	1.4	0
241	Reduced-Intensity or Myeloablative Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: A Side-By-Side Systematic Review/Meta-Analysis. Blood, 2016, 128, 3551-3551.	1.4	0
242	Incidence of Cytomegalovirus (CMV) Reactivation after Autologous Peripheral Blood Stem Cell Transplantation (ASCT) in 324 Patients with Multiple Myeloma and Lymphoma: A Single-Center Study at the American University of Beirut Medical Center (AUBMC). Blood, 2016, 128, 5824-5824.	1.4	0
243	Long-Term Follow up of Front-Line Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide (HiLO trial) for Treatment-Naïve Chronic Lymphocytic Leukemia. Blood, 2018, 132, 3150-3150.	1.4	0
244	Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) on the Outcomes of Angioimmunoblastic T-Cell Lymphoma (AITL): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. Blood, 2018, 132, 969-969.	1.4	0
245	Impact of Depression or Anxiety on Opioid and Benzodiazepine Use in Hospitalized Hematopoietic Stem Cell Transplantation (HSCT) Recipients. Blood, 2018, 132, 4852-4852.	1.4	0
246	Does Addition of Rituximab (R) to BEAM Conditioning Improve Outcomes of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Autologous Hematopoietic Cell Transplantation (auto-HCT)? Blood, 2019, 134, 785-785.	1.4	0
247	Efficacy of Allogeneic Hematopoietic Cell Transplantation (HCT) in Sickle Cell Disease: Results of a Systematic Review/Meta-Analysis. Blood, 2019, 134, 2106-2106.	1.4	0
248	Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Classical Hodgkin Lymphoma (cHL):a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis. Blood, 2019, 134, 3318-3318.	1.4	0
249	Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort. Blood, 2019, 134, 2588-2588.	1.4	0
250	Impact of Anti-CD19 CAR-T Axicabtagene Ciloleucel on Vaccine Titers of DTaP and MMR. Blood, 2019, 134, 5610-5610.	1.4	0
251	The Inpatient Unit in a Cancer Center. , 2022, , 15-20.		0
252	Significance of Degree of HLA Disparity When Using Haploidentical Donors with T-Replete PBSC and Post-Transplantation Cyclophosphamide (PTCy) in Acute Myeloid Leukemia (AML) in First Complete Hematologic Remission (CR1). Blood, 2021, 138, 3910-3910.	1.4	0

#	ARTICLE	IF	CITATIONS
253	Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience. <i>Blood</i> , 2021, 138, 1452-1452.	1.4	0
254	Unique Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (trALL) Following Therapy for Multiple Myeloma (MM). <i>Blood</i> , 2021, 138, 2285-2285.	1.4	0
255	A Calcineurin Inhibitor Free Graft Versus Host Disease (GVHD) Prophylaxis for Patients Undergoing Matched Related (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplant (Allo-HCT). <i>Blood</i> , 2021, 138, 3893-3893.	1.4	0
256	Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR. <i>Blood</i> , 2020, 136, 28-29.	1.4	0
257	Survival Outcomes in Blastic Plasmacytoid Dendritic Cell Neoplasm By First-Line Treatment and Stem Cell Transplant. <i>Blood</i> , 2020, 136, 15-15.	1.4	0
258	Impact of Cell of Origin (COO) on Long Term Outcomes Post Autologous Hematopoietic Cell Transplant in Patients with Relapsed/ Refractory Chemotherapy Sensitive De-Novo Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2020, 136, 42-43.	1.4	0